Healthcare sector in India is one of the largest in terms of employment as well as in revenue. Around 80 % of healthcare rests with private sector. The government healthcare is basically covered in rural area with primary healthcare centre, which provides succour to basic ailments. It also has speciality hospitals in major cities and reputed healthcare in metro cities. However, it is the private sector that provides majority of secondary, tertiary and quaternary care institutions with a major concentration in metros, tier I and tier II cities.
India also provides contrast in healthcare with high malnutrition, higher infant mortality rate, under vaccinated children and on the other side, India have medical tourism with world class facilities. The Indian healthcare industry is
Indian Council of Medical Research along with National Institute of Nutrition has launched a mobile App that offers comprehensive nutrition related information on a wide range of Indian food articles. The app is available on android and ioS called ?Nutrify India Now? is based on authentic and well researched India-specific databases. It provides data on several parameters such as protein, vitamin and mineral content of the food items, besides their calorific value. The good thing about is data on available on 17 languages and also classified by Indian food groups.
Odisha government is planning to launch a new healthcare scheme ?Biju Swasthya Kalyan Yojana,? which will provide health assistance to 70 lakh families. Under the Biju Swasthya Kalyan Yojana, 70 lakh people will be given health assistance of ? 5 lakh. A maximum of five people of a family will get the benefit under the scheme. The government has defined it as health assurance scheme and the entire cost will be borne by the state government. Benefits of the scheme will be availed in all government hospitals, right from sub-centres to district hospitals.
Advanced Research Centre for Powder Metallurgy & New Materials along with CSIR-NEERI has developed an eco-friendly sanitary pad incinerator. The incinerator named as GreenDispo will burn used napkins at a temperature of more than 800 degrees Centigrade, which other wise will allow growth of harmful pathogens causing serious health and environmental hazards. The device was developed using ceramic processing and shape aided by energy efficiencies design and manufacturing of Sowbal Aerothermis and environmental engineering as well as flue case emission control expertise of CSIR-NEERI. It may be noted, over 400 million of sanitary napkins are unsafely disposed in India per month.
After a negligence for several decades, the current union government has set up a ambitious target of bringing 100 million families under Universal Healthcare. It will be largely a state funded exercise under National Health Protecion Scheme which will provide health cover for Rs. 5.0 lakh per family. The move will provide fillip for demand in healthcare of medical equipment and other services. The scheme also envisages setting up of 1.5 lakh health and wellness centre with an investment of Rs. 12000 million. Now, the national market for healthcare is estimated at USD 100 billion.
Patients who need to be monitored are always kept under intensive care unit - which has an array of monitoring instruments which aids the doctor in clinical decision making. Now, with advent of cloud and remote access, many devices are in the market which provide continuous monitoring without expensive need for ICU. Now cloud connected smart remote monitors enable live streaming of patient vitals on central tablet and the mobile app. This can provide a inexpensive way to record vitals and can aid doctors who can access data anytime anywhere.
Gujarat Food and Drug Control Administration (FDCA) has appointed 4,000 retail pharmacies to distribute anti-TB drugs to patients not covered under the government healthcare programme. These designated pharmacies will stock and sell medicines for TB patients and help get patient?s details in an effective way. Gujarat FDCA is also supporting National Rural Health Mission (NRHM) by sharing relevant details of the patients not covered under the Revised National Tuberculosis Programme (RNTCP). There are around 37,650 retail and wholesale pharmacies in the state of Gujarat.
Council of Scientific and Industrial Research (CSIR) - Institute of Genomics & Integrative Biology (CSIR-IGIB) has decided to commercialise a set of 27 genetics tests it has developed over the years. The institute has entered into an agreement with Dr Lal PathLabs, which has a large network of network of diagnostic centres across the country, for licensing the genetic tests. These tests are expected to be launched in phases over the year. It is estimated that over 70 million Indians have been affected by rare genetic diseases. The new tests cover a variety of diseases/ disorders including movement disorders, motor neuron disease, mitochondrial disorders, developmental and inborn error of metabolism, and leukodystrophies. The project is funded through the Fast-Track Translation (FTT) Resear
Kerala Government is planning to produce anti-rabies vaccine in the state. It will produce the vaccine at the Institute of Animal Health and Veterinary Biologicals (IAH&VB) at Palode near Thiruvananthapuram, under the state Animal Husbandry Department. The institute at present produces viral and bacterial vaccines against cattle and poultry diseases. It plans to produce a total of 10 million doses of both human and animal anti-rabies vaccine. Currently, the state procures vaccine from Hyderabad-based Indian Immunologicals Limited (IIL), a subsidiary of National Dairy Development Board.
Indian government has launched Bedaquiline, a new anti-TB drug for Drug Resistant TB (DR TB) as part of the Revised National Tuberculosis Control Program (RNTCP). The drug is a new anti-TB drug for treatment of MDR-TB. This new class of drug is a diarylquinoline that specifically targets Mycobacterial ATP synthase, an enzyme essential for supply of energy to Mycobacterium tuberculosis and most other mycobacteria. This drug is indicated for use in the treatment of drug-resistant TB. Bedaquiline is being introduced at six identified tertiary care centres across India. These sites have advanced facilities for laboratory testing and intensive care for patients. Bedaquiline will be given to multi-drug resistant TB patients with resistance to either all fluoroquinolone and/or all second line inj